Golden Throat Holdings Group Co Ltd stock analysis
Want to see HK:6896 full AI Analyst Report?
Golden Throat Holdings Group Co Ltd (6896) Stock Price & Analysis
6896 Stock Chart & Stats
- Day’s Range
- HKD 1.88 - HKD 1.91
- 52-Week Range
- HKD 1.81 - HKD 3.80
- Previous Close
- HKD 1.92
- Volume
- N/A
- Average Volume (3M)
- 226.13K
- Market Cap
- HKD 1.42B
- Enterprise Value
- HKD 1.80B
- Total Cash (Recent Filing)
- HKD 1.08B
- Total Debt (Recent Filing)
- HKD 711.15M
- Price to Earnings (P/E)
- 5.7
- Beta
- 0.13
- Next Earnings
- Mar 31, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Jun 16, 2026
- Dividend Yield
- 17.99%
Bulls Say, Bears Say
Bulls Say
High Profitability
Sustained high gross and net margins indicate that Golden Throat has maintained effective pricing and cost control across multiple periods. This profitability provides internal funding capacity, supports brand investment, and offers resilience if revenue growth remains uneven over the next several quarters.
Manageable Leverage
Although leverage increased recently, the overall debt-to-equity position remains described as moderate and historical returns on equity have been healthy. This suggests the business has produced attractive shareholder returns without relying on excessive financial leverage, preserving some balance-sheet flexibility.
Historical Cash Conversion
The company’s historical ability to convert accounting earnings into free cash flow supports the quality of its underlying profitability. While the latest year was weaker, this prior pattern indicates that the operating model has demonstrated cash-generative characteristics that could re-emerge as working-capital or reinvestment effects normalize.
Bears Say
Revenue Contraction
Recent revenue weakness and a history of intermittent contraction point to an uneven growth profile rather than a consistently expanding demand base. A bumpier top line can limit operating leverage, make future earnings less predictable, and require continued brand and product execution to restore sustained growth.
Cash Flow Deterioration
The sharp 2025 decline in operating and free cash flow materially weakens near-term funding capacity despite strong reported margins. Lower cash generation can constrain dividends, reinvestment, and debt reduction, while the size of the swing raises questions about the durability and timing of cash conversion.
Higher Leverage
The increase in debt relative to equity reduces financial flexibility at the same time that revenue, profit, and cash generation have softened. Higher leverage may increase sensitivity to further earnings weakness and leaves less balance-sheet capacity for investment or shareholder distributions if operating conditions deteriorate.
Golden Throat Holdings Group Co Ltd News
6896 FAQ
What was Golden Throat Holdings Group Co Ltd’s price range in the past 12 months?
What is Golden Throat Holdings Group Co Ltd’s market cap?
When is Golden Throat Holdings Group Co Ltd’s upcoming earnings report date?
How were Golden Throat Holdings Group Co Ltd’s earnings last quarter?
Is Golden Throat Holdings Group Co Ltd overvalued?
Does Golden Throat Holdings Group Co Ltd pay dividends?
What is Golden Throat Holdings Group Co Ltd’s EPS estimate?
How many shares outstanding does Golden Throat Holdings Group Co Ltd have?
What happened to Golden Throat Holdings Group Co Ltd’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Golden Throat Holdings Group Co Ltd?
What is the TipRanks Smart Score and how is it calculated?
Golden Throat Holdings Group Co Ltd Stock Smart Score
Company Description
Golden Throat Holdings Group Co Ltd
Golden Throat Holdings Group Company Limited operates as an investment holding entity primarily engaged in the production and distribution of pharmaceutical goods, health-focused foods, and various other products within the People's Republic of China. Among its offerings are the widely recognized Golden Throat lozenges, an over-the-counter remedy designed to alleviate discomfort from sore and dry throats, as well as hoarseness often stemming from acute pharyngitis. The company further expands its Golden Throat lozenge line with products like Dule lozenges and their sugar-free counterparts, available in diverse flavors including orange, fructus momordicae, chrysanthemum, American ginseng, and hawthorn. Additionally, Golden Throat manufactures the Yinxingye tablet, formulated to enhance blood circulation, disperse blood stasis, and clear energy pathways. Its product portfolio also encompasses herbal vegetable beverages, crafted to provide vocal comfort and soothe irritated throats. Beyond its domestic market, the company extends its reach globally, exporting its range of products to countries and regions such as the United States, Canada, Russia, the European Union, Australia, Southeast Asia, the Middle East, Mexico, and across Africa. Established in 1956, Golden Throat Holdings Group Company Limited maintains its corporate headquarters in Liuzhou, within the People's Republic of China.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Yong Zeng
- Employees
- 824
- Website
- www.gxjsz.com
- Address
- CN
Golden Throat Holdings Group Co Ltd (6896) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 4 | 15 |
| Technical Analysis | 3 | 4 | 3 |
| Moving Averages | 0 | 0 | 12 |










